Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 2/20 | 0.43 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.41 |
| ▸ | WNT1 | P04628 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15064621 | 0.80 | PRMT5 (0.55) | NTRK1IKBKETTKGSTP1PRMT5 | |
| SCHEMBL19149769 | 0.74 | NTRK1 (0.53) | NTRK1IKBKETTKGSTP1GSK3B | |
| SCHEMBL570398 | 0.74 | IKBKE (0.48) | RAB9ASMN1; SMN2NTRK1IKBKETTK | |
| SCHEMBL5386440 | 0.73 | TTK (0.72) | KDM4ENTRK1TTKGSK3BCDC7 | |
| SCHEMBL571162 | 0.72 | CMKLR1 (0.47) | RAB9ASMN1; SMN2GSTP1NPC1L3MBTL1 | |
| SCHEMBL1663830 | 0.71 | TTK (0.64) | RAB9AKDM4ESMN1; SMN2NTRK1IKBKE | |
| SCHEMBL6997227 | 0.71 | TTK (0.50) | KDM4ESMN1; SMN2NTRK1TTKWNT1 | |
| SCHEMBL23645939 | 0.69 | IKBKE (0.46) | RAB9ASMN1; SMN2NTRK1IKBKEGSTP1 | |
| SCHEMBL14015023 | 0.69 | KDM4E (0.58) | TRPA1RAB9AKDM4ESMN1; SMN2TTK | |
| SCHEMBL6997886 | 0.69 | ALDH1A1 (0.46) | RAB9AKDM4ESMN1; SMN2TTKMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601192-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-9029536-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-12 | — | — | US | disclosed |
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172292-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE10A, PDE3A, PDE2A | TRPA1 3995/4885RAB9A 64/4885KDM4E 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.